LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced it will present three abstracts supporting the use of implantable neuromodulation technology to treat chronic heart failure during the American College of Cardiology 68th Annual Scientific Session (ACC 2019) from March 16-18 in New Orleans, USA.
The LivaNova VITARIA® System delivers Autonomic Regulation Therapy (ART) using Vagus Nerve Stimulation (VNS) to treat patients with chronic, symptomatic heart failure with reduced ejection fraction (HFrEF). VITARIA is currently being used to study the effects of ART in a prospective, international, randomized, controlled clinical trial (ANTHEM-HFrEF Pivotal Study). Patients meeting all inclusion and exclusion criteria are randomized (2:1) to either the treatment arm or the control arm, and are followed thereafter to determine the safety and efficacy of the system and therapy.
The VITARIA System has received Expedited Access Pathway designation as a Breakthrough Technology from the U.S. Food and Drug Administration. If approved, the VITARIA System could be the first in its class for treating chronic heart failure.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.